跳至主要内容
临床试验/NCT04814680
NCT04814680已完成不适用

A Non-Interventional Pilot Study to Evaluate A Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate From Digital Retinal Images

AstraZeneca1 个研究点 分布在 1 个国家目标入组 301 人开始时间: 2021年11月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
301
试验地点
1
主要终点
To assess successful use of methodology for retinal image acquisition, BP (ABPM or manual), HbA1C (laboratory based or point of care test) and e-GFR measurement.

研究概览

简要总结

This is a non-interventional pilot study with the following objectives:

  • Establish scalable methodology for collection of retinal images, blood pressure (BP) and laboratory-based assessments
  • Compare the results of a machine-learning algorithm in predicting BP, glycated haemoglobin (HbA1c) and estimated glomerular filtration rate (eGFR) from digital retinal images with clinical and laboratory-based measures
  • Determine the required sample size needed to support a future study to fully validate the machine-learning algorithm

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
35 Years 至 130 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant must be ≥ 35 years of age, at the time of signing the informed consent.
  • With or without DM (at least 50% of participants will have an HbA1c ≥ 6.5%* and/or a known diagnosis of DM)
  • Male or female (at least 40% of participants must be male, and at least 40% must be female)
  • Capable of giving signed informed consent as described in Appendix A

排除标准

  • As judged by the investigator, any evidence of a medical condition which in the investigator's opinion makes it undesirable for the participant to participate in the study for example, but not limited to, if a participant is critically unwell or requiring ongoing emergency treatment
  • Any known eye condition that may preclude clear imaging of the retina for example; cataracts
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
  • Previous enrolment in the present study with the exception of roll-in participants who may be re-screened and re-enrolled.

结局指标

主要结局

To assess successful use of methodology for retinal image acquisition, BP (ABPM or manual), HbA1C (laboratory based or point of care test) and e-GFR measurement.

时间窗: up to 66 day

Proportion of participants with completed study procedures and interpretable results including both retinal images, systolic and diastolic BP (ABPM or manual), HbA1c (laboratory based or point of care test) and eGFR at Visit 1

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验